Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1913-1924
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1913
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1913
Table 3 Adverse events
| CTCAE grade ≥ 3 | CTCAE grade 4 | |||
| n | % | n | % | |
| Any | 34 | 28.6 | 2 | 1.7 |
| Hematological (n = 25) | ||||
| Leukopenia | ||||
| Neutropenia | 4 | 3.4 | 1 | 0.8 |
| Thrombocytopenia | 3 | 2.5 | 1 | 0.8 |
| Anemia | 6 | 5.0 | 1 | 0.8 |
| 12 | 10.1 | 0 | 0 | |
| Non-hematological (n = 29) | ||||
| Bleeding | ||||
| Diarrhea | 4 | 3.4 | 0 | 0 |
| Nausea | 9 | 7.6 | 1 | 0.8 |
| Vomiting | 3 | 2.5 | 0 | 0 |
| Stomatitis | 6 | 5.0 | 0 | 0 |
| Dermal | 2 | 1.7 | 0 | 0 |
| HFS | 1 | 0.8 | 0 | 0 |
| 4 | 3.4 | 0 | 0 | |
- Citation: Mullin G, Sternschuss M, Landman Y, Sulkes A, Brenner B. Mitomycin C and capecitabine: An additional option as an advanced line therapy in patients with metastatic colorectal cancer. World J Gastrointest Oncol 2023; 15(11): 1913-1924
- URL: https://www.wjgnet.com/1948-5204/full/v15/i11/1913.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i11.1913